Cellular Origins
Dan Strange currently serves as the Chief Technology Officer at Cellular Origins, a TTP Company, where the focus is on advancing scalable and efficient manufacturing of cell and gene therapies through innovative technology solutions. With prior experience as an Employee Trustee Director at TTP Group, Dan played a key role in representing employee interests within the company. Dan's background includes significant contributions to future cell therapy automation at TTP plc, as well as early experience as a Biomedical Engineer at Columna Pty Ltd, where work involved the development of a minimally invasive treatment for back pain. Dan holds a Ph.D. in Tissue Engineering and an M.A./M.Eng. in Engineering for the Life Sciences from the University of Cambridge.
This person is not in any teams
Cellular Origins
Cellular Origins, a TTP company, is focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies. Created to provide therapeutic developers access to the equipment they want, at the capacity they need, Cellular Origins’ proprietary technology addresses the challenges associated with manufacturing at scale, with an elegant solution for automated sterile fluidic interconnection that reduces cost and labour, eliminating human error, and increasing efficiency.